Wells Fargo & Company Increases Gilead Sciences (NASDAQ:GILD) Price Target to $150.00

Gilead Sciences (NASDAQ:GILD) had its price target upped by stock analysts at Wells Fargo & Company from $145.00 to $150.00 in a research report issued on Wednesday,MarketScreener reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 26.12% from the stock’s current price.

GILD has been the subject of a number of other research reports. BMO Capital Markets set a $135.00 price objective on shares of Gilead Sciences in a report on Tuesday, November 25th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. TD Cowen raised their price objective on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Finally, Mizuho increased their target price on Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $130.96.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $118.93 on Wednesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The stock’s fifty day moving average price is $121.28 and its two-hundred day moving average price is $115.53. Gilead Sciences has a one year low of $88.57 and a one year high of $128.70. The firm has a market cap of $147.56 billion, a price-to-earnings ratio of 18.44, a P/E/G ratio of 0.67 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts forecast that Gilead Sciences will post 7.95 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.23, for a total value of $313,075.00. Following the completion of the transaction, the chief financial officer owned 154,555 shares of the company’s stock, valued at approximately $19,354,922.65. This represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the sale, the director directly owned 8,920 shares in the company, valued at $1,115,713.60. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 135,757 shares of company stock valued at $16,616,127 over the last ninety days. 0.27% of the stock is owned by insiders.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Activest Wealth Management lifted its stake in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. GoalVest Advisory LLC increased its holdings in Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC acquired a new position in Gilead Sciences in the 3rd quarter worth about $26,000. Harbor Asset Planning Inc. bought a new position in Gilead Sciences in the second quarter valued at about $27,000. Finally, Putney Financial Group LLC raised its position in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.